OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
May 23, 2024 • 17min
S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
May 20, 2024 • 12min
S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa
Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.
May 13, 2024 • 8min
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
May 9, 2024 • 13min
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
May 6, 2024 • 17min
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.
May 2, 2024 • 24min
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and more.
Apr 29, 2024 • 25min
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Apr 22, 2024 • 9min
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Dr Usmani discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma patients who have had at least 1 prior line of therapy. Topics include comparing CAR-T cell therapy benefits to standard care regimens, impacts on earlier treatment settings, patient accessibility, a comparative study of cilta-cel vs. standard care regimens, FDA advisory committee meeting insights, safety, and the role of cilta-cel in multiple myeloma treatment.
Apr 18, 2024 • 14min
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
Apr 11, 2024 • 42min
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.
